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iomonitoring of tissues such as blood, urine, and
breast milk is an extremely valuable tool for identi-
fying population exposure to harmful chemicals. The
data gathered through biomonitoring can provide guid-
ance on how to prioritize toxicological research, and can
result in measures to control and prevent exposure.
Despite these benefits, however, “tremendous challenges”
still surround the use of this technology, according to
Human Biomonitoring for Environmental Chemicals, a
report released 24 July 2006 by a committee of the
National Research Council (NRC). The report noted, for
instance, that there should be much more emphasis on
communicating the results of studies in the design of the
research. It also called for a “consistent rationale for
selecting chemicals to be studied based on exposure and
public health concerns.”
More Data than Information
The report was requested in an EPA appropriation in a
2004 House–Senate Conference Report. The NRC com-
mittee was charged with the goal of reviewing current
practices and recommending ways to improve the inter-
pretation and uses of human biomonitoring data on envi-
ronmental chemicals.
The committee held four public sessions in which it
heard presentations on the conduct and importance of
biomonitoring research from a variety of authorities repre-
senting government, industry, and academia.
Biomonitoring is going to play a major role in the future
of environmental health, says committee chair Thomas
Burke, a professor of health policy and management at the
Johns Hopkins University Bloomberg School of Public
Health. “Our biggest challenge is figuring out what this
biomonitoring data means in terms of public health, par-
ticularly,” he says.
According to the report, biomonitoring has been
extremely valuable in tracing time trends in children’s
exposure to lead, thus validating the success of public
health initiatives such as the removal of lead from gasoline.
Biomonitoring has also played an important role in assess-
ing exposures to mercury and secondhand tobacco smoke,
and thus in guiding development of exposure prevention
strategies. 
These success stories notwithstanding, there are few
chemicals about which enough is known to make public
health pronouncements and provide risk information with
confidence. This, the report notes, stands in contrast to
scientists’ ability to actually detect chemicals in people.
“The problem is that the technology for measurement has
in many cases exceeded the available information on ani-
mal health effects, let alone human health effects,” says
committee member Mark Cullen, a professor of medicine
and public health at Yale University School of Medicine. 
One reason for the gap is that there is not adequate test-
ing of chemicals in the United States before they are mar-
keted, says Philip Landrigan, a professor of community and
preventive medicine and pediatrics at Mount Sinai School
of Medicine who peer-reviewed. “We basically assume that
chemicals are harmless until some injury is found,” he says.
Carol Henry, a member of the NRC committee and
vice president for industry performance programs at the
American Chemistry Council (ACC), notes that the diffi-
culty of interpreting biomonitoring data and their rela-
tionships to exposure information is a significant barrier to
more effective applications of such data—in particular, for
implementing intervention strategies.
for BiomonitoringLeveraging Resources
“There’s a lot of useful information just
about exposure to people that can be gained
from doing biomonitoring and not just rely-
ing on models and assumptions about what’s
getting into people,” says John Balbus, direc-
tor of health programs at Environmental
Defense. The NRC report points to the
CDC’s ongoing National Report on Human
Exposure to Environmental Chemicals as offer-
ing the most comprehensive biomonitoring
information on a representative sample of
the American population. The third
National Report, issued in July 2005, pro-
vides exposure information about 148 chem-
icals in a sampling of 2,400 people.
Periodic notices in the Federal Register
ask for chemicals to be nominated for study
as part of the National Report. A number of
criteria are used in selecting the chemicals to
be measured by the CDC. These include the
degree to which people are exposed to them,
the gravity of the known or suspected health
effects, the availability of accurate, repeat-
able methods to measure the chemicals, and
the cost of testing. Scientists at the CDC’s
National Center for Environmental Health
(NCEH) and outside reviewers use these cri-
teria to make the final selection. 
The CDC report is not a report on health,
asserts John Osterloh, chief medical officer at
the NCEH Division of Laboratory Sciences; it
is a report on exposure. “We’re very cautious
in the report to say that we don’t know
whether or not the levels are related to health
effects,” he says. “Better exposure information
will produce better decisions to protect peo-
ple’s health.” The exposure information, he
says, can steer science toward studying possible
health effects of chemicals that are in people. 
The NRC report points to changes it
would like to see in the way the CDC goes
about this survey. “We want to improve the
chemical selection process to include more
input,” says Burke. “We feel there should be
a multiagency group to look at our existing
body of knowledge to make sure we’re look-
ing at the right kinds of things. We would
like to get the program to look at what
emerging issues might be, based upon both
potential for population exposure and evi-
dence of potential public health impacts.”
The report notes that the agencies routinely
involved in selecting chemicals should
include not just the CDC but also the EPA,
the NIEHS, the National Toxicology
Program, the FDA, and the USDA.
The NRC committee further states that
the CDC should improve its efforts to com-
municate the results of its survey to the pub-
lic, agency members, and policy makers.
“The CDC comes out with a report on expo-
sure, but really leaves it up to the media to
interpret the potential implications,” says
Burke. According to the NRC report, com-
municating results of biomonitoring has not
played as important a role as it should—too
often in such studies, interpreting and com-
municating the results would appear to have
been “an afterthought,” notes Burke.
The design of communication strategies
should take a higher priority so the public
can be better informed. The strategy should
include being ready to answer important
questions that the public will ask, Burke
says, such as why the chemical was selected
and what is and isn’t known about it. “This
[strategy] can be designed up front to facili-
tate the process,” he says.
When there aren’t answers to such ques-
tions, Burke says, it’s perfectly legitimate for
scientists to voice their ignorance. “But,” he
adds, “when you don’t know, it’s really
important to communicate how you’re going
about learning.”
But how does one craft messages about
the presence of environmental chemicals in
people’s bodies? As the report notes, “Absence
of evidence of effects is not identical with evi-
dence of absence of effects—a distinction
that must be made clear to constituents.”
Researchers may sometimes appropriately
conclude that, while high biomarker levels are
not necessarily bad, low levels are not necessar-
ily good; sometimes it is difficult to come up
with easy answers to questions on the health
impact of chemicals. The NRC committee
calls for empirical research on how to convey
such a conclusion without engendering the
twin problems of baseless concern or apathy.
Closing the Gaps
The NRC report also points to the need for
research that applies biomarkers for envi-
ronmental chemicals in animal toxicology
testing to understand how these biomarkers
relate to adverse effects. “Right now we
know what [test animals’] intake dose is,
but we don’t know how that translates into
biomarker levels,” says Burke. “For exam-
ple, it would be so much more informative
to the interpretation process if we could
compare blood levels in test animals to
blood levels in humans.” Traditionally, he
explains, toxicology studies have not exam-
ined blood levels in animal models. 
As one example he points to perfluorooc-
tanoic acid (PFOA), which is used in making
Teflon and materials used in many consumer
products such as food packaging and stain-
resistant clothing. “Although we have found
that there is widespread presence [of PFOA]
in the environment and people, we have lim-
ited testing data to help us understand just
how much the low levels found throughout
the population might impact public health,”
says Burke. (Despite the uncertainty about
the health effects of these low levels of PFOA,
DuPont and other chemical companies using
the compound pledged in January 2006 to
work toward eliminating it by 2015.)
The need to make sense of human bio-
monitoring data and understand them as
markers of exposure stimulated the ACC to
hold a workshop shortly after the NRC report
was issued, with the goal of identifying knowl-
edge gaps and research needs. Among the
concerns examined is a critical need for under-
standing what is found in the body and where
and how the exposure occurred, explains Tina
Bahadori, a senior scientist with the ACC
who co-chaired the workshop. “Ultimately
the goal is to know how you would intervene
to either modulate the exposure or ascertain
for sure there is no concern. If you don’t
know where and how it came from, there is
no way you can do that,” she says.
Biomonitoring has also drawn the atten-
tion of the California legislature. Law makers
this year have passed a bill to set up a state bio-
monitoring program, which would sample
state residents on a voluntary basis. According
to Richard Jackson, an adjunct professor of
environmental health sciences at the
University of California, Berkeley, such a pro-
gram is important, considering some of the
characteristics of chemical use in the state.
“California uses well over a quarter of the most
toxic pesticides in the nation,” Jackson says.
“We have a series of high-tech industries in the
state that use chemicals that are really not used
in other parts of the country.” As former direc-
tor of the NCEH, Jackson led the CDC’s bio-
monitoring program from 1994 to 2003.
The new law makes California the first
state to legislate a biomonitoring program. A
16-member scientific advisory panel will be
appointed by legislative leaders and the heads
of the California EPA and Department of
Health Services by 1 July 2007 to recom-
mend design and implementation of the
program. The program would select commu-
nities that would be “reflective of the eco-
nomic, racial, and ethnic composition of the
state,” according to the law. The law, howev-
er, also says that biomonitoring samples may
be taken from so-called nongeographical
communities—that is, people who may share
a common chemical exposure because they
have similar jobs or lifestyles. 
As the California legislation and the
NRC report demonstrate, biomonitoring is
becoming an important tool in assessing envi-
ronmental health. The report describes it as
“a potentially powerful new lens for examin-
ing public exposure to toxic chemicals.” Yet
as the report also makes plain, effective use of
this tool demands that the research commu-
nity address a number of technical and com-
munication challenges.
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